Calidi Biotherapeutics 관리

관리 기준 확인 4/4

Calidi Biotherapeutics CEO는 Allan Camaisa, Feb2018 에 임명되었습니다 의 임기는 6.75 년입니다. 총 연간 보상은 $ 436.51K, 58.9% 로 구성됩니다. 58.9% 급여 및 41.1% 보너스(회사 주식 및 옵션 포함). 는 $ 148.05K 가치에 해당하는 회사 주식의 0.4% 직접 소유합니다. 148.05K. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 3.8 년입니다.

주요 정보

Allan Camaisa

최고 경영자

US$436.5k

총 보상

CEO 급여 비율	58.9%
CEO 임기	6.8yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Allan Camaisa 의 보수는 Calidi Biotherapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

보상 대 시장: Allan 의 총 보상 ($USD 436.51K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 647.72K ).

보상과 수익: Allan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Allan Camaisa (64 yo)

6.8yrs

테뉴어

US$436,512

보상

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

리더십 팀

이름	위치	테뉴어	보상	소유권
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
Wendy Pizarro Campbell	Chief Administrative Officer	3.2yrs	US$295.40k	0.084% $ 31.3k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.4yrs	US$400.10k	0.22% $ 81.9k
Andrew Jackson	Chief Financial Officer	1.1yrs	데이터 없음	데이터 없음
Stephen Thesing	Chief Business Officer	8.8yrs	데이터 없음	0.24% $ 91.0k

6.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: CLDI 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
James Schoeneck	Independent Director	4.3yrs	US$109.56k	0.53% $ 197.4k
W.K. Yung	Member of Medical Advisory Board	2.4yrs	데이터 없음	데이터 없음
Ewa Carrier	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
George Peoples	Independent Director	less than a year	데이터 없음	0.00089% $ 331.8
Scott Leftwich	Independent Vice-Chairman of the Board	5.5yrs	US$179.89k	1.23% $ 459.1k
Alan Stewart	Independent Director	1.1yrs	US$120.56k	0.029% $ 10.7k
Santosh Kesari	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Dmitriy Zamarin	Member of Scientific Advisory Board	3.8yrs	데이터 없음	데이터 없음
Ashok Srivastava	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Karen Aboody	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Maciej Lesniak	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: CLDI 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Calidi Biotherapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령